J.P. Morgan Private Wealth Advisors LLC Invests $1.57 Million in Medpace Holdings, Inc. (NASDAQ:MEDP)

J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 6,463 shares of the company’s stock, valued at approximately $1,565,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Handelsbanken Fonder AB lifted its stake in Medpace by 46.9% during the second quarter. Handelsbanken Fonder AB now owns 4,700 shares of the company’s stock valued at $1,129,000 after buying an additional 1,500 shares in the last quarter. Atria Investments Inc purchased a new stake in Medpace during the third quarter valued at about $1,013,000. Coldstream Capital Management Inc. purchased a new stake in Medpace during the second quarter valued at about $218,000. Larson Financial Group LLC purchased a new stake in Medpace during the third quarter valued at about $2,002,000. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in Medpace by 13.3% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 3,755 shares of the company’s stock valued at $909,000 after buying an additional 440 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Medpace

In other news, VP Susan E. Burwig sold 10,391 shares of the stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $304.15, for a total value of $3,160,422.65. Following the completion of the sale, the vice president now directly owns 17,292 shares of the company’s stock, valued at $5,259,361.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP Susan E. Burwig sold 10,391 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $304.15, for a total value of $3,160,422.65. Following the transaction, the vice president now owns 17,292 shares in the company, valued at $5,259,361.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Medpace Investors, Llc sold 33,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $283.42, for a total value of $9,352,860.00. Following the completion of the transaction, the insider now owns 5,856,947 shares in the company, valued at approximately $1,659,975,918.74. The disclosure for this sale can be found here. Insiders sold 210,391 shares of company stock valued at $58,708,131 over the last three months. 25.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, Robert W. Baird upped their price objective on shares of Medpace from $302.00 to $312.00 and gave the company an “outperform” rating in a research note on Wednesday, January 17th.

Read Our Latest Stock Analysis on MEDP

Medpace Price Performance

NASDAQ MEDP opened at $326.39 on Monday. The company has a 50 day simple moving average of $297.61 and a 200-day simple moving average of $273.00. The firm has a market capitalization of $10.01 billion, a price-to-earnings ratio of 38.22 and a beta of 1.29. Medpace Holdings, Inc. has a 52-week low of $167.00 and a 52-week high of $331.10.

Medpace Company Profile

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Read More

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPFree Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.